Soligenix, Inc. (SNGX)
|52 Week Range||0.42-10.95|
|1y Target Est||-|
|DCF Unlevered||SNGX DCF ->|
|DCF Levered||SNGX LDCF ->|
|Debt / Equity||54.02%||Buy|
Upgrades & Downgrades
Latest SNGX news
Soligenix shares spike after T-cell lymphoma candidate HyBryte aces compatibility study results
4 May 2023
Soligenix (NASDAQ:SNGX) shares more than doubled on Thursday after the biopharmaceutical company announced positive results from a compatibility study of its investigational therapeutic HyBryte in cut...
Soligenix stock slumps as cancer drug application is knocked back
14 February 2023
Soligenix (NASDAQ:SNGX) slumped in Tuesday's early deals after revealing its cancer drug has been knocked back by the US Food and Drug Administration. The company, in a statement, told investors that ...
Soligenix Invited to Present at the Virtual Investor Summit Event
19 January 2023
Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market PRINCETON, N.J. , Jan. 19, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the C...
7 Stocks to Add to Your 10x Watchlist
16 December 2022
There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfol...
Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference
11 November 2022
Princeton, New Jersey--(Newsfile Corp. - November 11, 2022) - Investor Summit Group, today announced that Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company) will attend the Q4 Investor Summit l...
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma
5 October 2022
Soligenix is an underfollowed biotech company trading at a $20 million market cap. The company is about to file an NDA for HyBryte, which I expect to become a first-in-class treatment in cutaneous T-c...
Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study
20 July 2022
Soligenix Inc (NASDAQ: SNGX) announced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL) had been published in the Journal of the Ame...
Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants
17 March 2022
Soligenix Inc (NASDAQ: SNGX) announced the results of a booster vaccination study using CiVax (heat-stable COVID-19 subunit vaccine program) in non-human primates (NHPs). The data demonstrated rapid ...
Soligenix to Present at the Q1 Virtual Investor Summit
2 March 2022
PRINCETON, N.J., March 2, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...